These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28521433)

  • 1. Effect of selective small molecule inhibitors on MMP-9 and VEGFR-1 expression in p16-positive and -negative squamous cell carcinoma.
    Kramer B; Schultz JD; Hock C; Sauter A; Stuck BA; Hörmann K; Birk R; Aderhold C
    Oncol Lett; 2017 May; 13(5):3269-3276. PubMed ID: 28521433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapies in HPV-positive and -negative HNSCC - Alteration of EGFR and VEGFR-2 Expression In Vitro.
    Kramer B; Hock C; Birk R; Sauter A; Stuck BA; Hörmann K; Schultz JD; Aderhold C
    Anticancer Res; 2016 Jun; 36(6):2799-807. PubMed ID: 27272791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIF-1α and mTOR - Possible Novel Strategies of Targeted Therapies in p16-positive and -negative HNSCC.
    Kramer B; Polit M; Birk R; Rotter N; Aderhold C
    Cancer Genomics Proteomics; 2018; 15(3):175-184. PubMed ID: 29695399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Tyrosine Kinase Inhibitors and Everolimus on TGFβ1 and TGF-β Receptor 2 in Squamous Cell Carcinoma Cells.
    Huber L; Knüttel MT; Kramer B; Zaubitzer L; Lammert A; Scherl C; Rotter N; Häussler D
    Anticancer Res; 2024 Aug; 44(8):3287-3294. PubMed ID: 39060052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-2 and -14 in p16-positive and -negative HNSCC after exposure To 5-FU and docetaxel In Vitro.
    Aderhold C; Umbreit C; Faber A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2014 Sep; 34(9):4929-37. PubMed ID: 25202075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus.
    Huber L; Birk R; Knuettel M; Rotter N; Aderhold C; Scherl C; Lammert A; Jungbauer F; Kramer B
    Anticancer Res; 2020 Oct; 40(10):5621-5630. PubMed ID: 32988886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.
    Kramer B; Kneissle M; Birk R; Rotter N; Aderhold C
    Anticancer Res; 2018 May; 38(5):2723-2731. PubMed ID: 29715092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small molecules alter VEGFR and PTEN expression in HPV-positive and -negative SCC: new hope for targeted-therapy.
    Aderhold C; Faber A; Umbreit C; Chakraborty A; Bockmayer A; Birk R; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Mar; 35(3):1389-99. PubMed ID: 25750290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Treatment of HPV16-positive and -negative SCC Cells With Small Molecule Tyrosine Kinase Inhibitors and Everolimus Affects MMP2 and MMP14 Expression.
    Huber L; Birk R; Knuettel M; Rotter N; Aderhold C; Scherl C; Lammert A; Jungbauer F; Kramer B
    Anticancer Res; 2022 Jul; 42(7):3403-3411. PubMed ID: 35790279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma.
    Kramer B; Schell A; Aderhold C; Huber L; Mueller CE; Rotter N; Birk R
    Anticancer Res; 2020 Jul; 40(7):3847-3855. PubMed ID: 32620624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Umbreit C; Aderhold C; Faber A; Sauter A; Hofheinz RD; Stern-Straeter J; Hoermann K; Schultz JD
    Oncol Rep; 2014 Aug; 32(2):668-76. PubMed ID: 24890748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
    Kramer B; Hock C; Schultz JD; Lammert A; Kuhlin B; Birk R; Hörmann K; Aderhold C
    Anticancer Res; 2017 Jun; 37(6):2845-2852. PubMed ID: 28551620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.
    Aderhold C; Faber A; Grobschmidt GM; Chakraborty A; Bockmayer A; Umbreit C; Birk R; Stern-Straeter J; Hörmann K; Schultz JD
    Anticancer Res; 2013 Dec; 33(12):5385-93. PubMed ID: 24324073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC.
    Birk R; Schell A; Aderhold C; Hoch S; Huber L; Mueller CE; Lammert A; Scherl C; Rotter N; Sommer JU; Kramer B
    Anticancer Res; 2020 Nov; 40(11):6195-6203. PubMed ID: 33109556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
    Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
    Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Small-molecule Tyrosine Kinase Inhibitors on PDGF-AA/BB and PDGFRα/β Expression in SCC According to HPV16 Status.
    Huber L; Birk R; Rotter N; Aderhold C; Lammert A; Jungbauer F; Kramer B
    Anticancer Res; 2020 Feb; 40(2):825-835. PubMed ID: 32014925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.
    Umbreit C; Erben P; Faber A; Hofheinz RD; Aderhold C; Weiss C; Hoermann K; Wenzel A; Schultz JD
    Anticancer Res; 2015 Jul; 35(7):3801-10. PubMed ID: 26124325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of MMP-2 and -14 expression by imatinib in HPV-positive and -negative squamous cell carcinoma.
    Faber A; Sauter A; Hoedt S; Hoermann K; Erben P; Hofheinz RD; Sommer U; Stern-Straeter J; Schultz DJ
    Oncol Rep; 2012 Jul; 28(1):172-8. PubMed ID: 22576800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
    Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
    Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapeutic alteration of β-catenin and c-kit expression by imatinib in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
    Schultz JD; Sommer JU; Hoedt S; Erben P; Hofheinz RD; Faber A; Thorn C; Hörmann K; Sauter A
    Oncol Rep; 2012 Jan; 27(1):270-80. PubMed ID: 21993766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.